Comparison of the effects of three kinds of glucose ‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study

ConclusionsThe present study showed that the decrease of visceral fat area and the increase of adiponectin level contributed to the improvement of NAFLD in patients with type  2 diabetes mellitus. Furthermore, dapagliflozin and pioglitazone exerted equivalent beneficial effects on NAFLD in patients with type 2 diabetes mellitus, although it seemed that these two drugs had different mechanisms of action.

Source: Journal of Diabetes Investigation - May 25, 2020 Category: Endocrinology Authors: Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima, Yoshiro Fushimi, Yurie Hirata, Akihito Tanabe, Fuminori Tatsumi, Hidenori Hirukawa, Junpei Sanada, Kenji Kohara, Shintaro Irie, Tomohiko Kimura, Yoshiko Nakamura, Momoyo Nishioka, Atsushi Oba Tags: Clinical Trial Source Type: research